Rockville, Md. — January 4, 2022 — Psomagen, Inc., has completed training for OIink® Target and Olink® Explore panels to add them to their service offerings for protein biomarker research. This program trains Psomagen labs to provide high-multiplex immunoassays with a high standard for data quality.
Olink panels make use of their proprietary proximity extension assay (PEA) technology, which uses antibodies with DNA tags to measure the protein profile in patient samples with high specificity. This has helped researchers make groundbreaking advancements in inflammation and disease studies.
“This training is a very exciting step for Psomagen labs and our customers,” says Dr. Su Hong, Psomagen CEO. “It is a great opportunity to expand further into protein research and multiomics studies."
Olink® Target 48 cytokine panels focus on proteins related to important disease mechanisms and inflammatory processes. With only a 1 µl sample, researchers gain insights into 45 proteins carefully selected to provide the most valuable insights for inflammation studies. Olink® Target 96 panels offer a larger set of proteins for analysis, also focusing on key disease factors. The service touts high sensitivity and accuracy with very limited sample sizes.
Olink® Explore panels provide analysis for protein biomarkers and cover many important biological pathways. Olink® Explore 1536 can analyze up to 88 samples at once.
Psomagen has undergone training and quality control assessments to become a trusted Olink® service provider. This program ensures that Psomagen clients are receiving accurate, high-quality data from Target and Explore panels.
Moving forward, Psomagen will add additional Olink® options to their services. These additional options will give Psomagen customers additional options for flexible, targeted protein research.
About Psomagen, Inc.
Psomagen, Inc., formerly Macrogen Corp, is a North American integrative omics solutions and contract laboratory services provider. The company makes cutting-edge technology and data analysis accessible to the clinical and academic markets. With both CLIA-certified and CAP-accredited facilities, their team delivers only the highest-quality integrative multi-omics data using best-in-class DNA, RNA, and protein analysis systems. In conjunction with its bioinformatics capabilities, Psomagen offers a path to insights that is both simple and affordable. Learn more at psomagen.com.
Dr. Harold Nuñez
(301) 251-1007 x531
Olink Proteomics (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink Proteomics provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st-century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America, and Asia. Olink Proteomics is headquartered in Uppsala, Sweden.